Literatur
-
1
Alfthan G, Pekkanen J, Jauhiainen M. et al .
Relation of serum homocysteine and lipoprotein(a)
concentrations to atherosclerotic disease in a prospective Finnish
population based study.
Atherosclerosis.
1994;
106
9-19
-
2
Allenberg J, Brandt T, Thron A.
Percutane
transluminale Angioplastie und Stenting bei Stenosen der A. carotis
interna.
Nervenarzt.
1999;
70
314
-
3
American Diabetes Association .
Clinical
practice recommendations.
Diabetes Care.
1998;
21
1-89
(suppl.1))
-
4
Anderson J L, Muhlestein J B, Carlquist J. et al .
Randomized secondary prevention trial of
azithromycin in patients with coronary artery disease and serological
evidence for Chlamydia pneumoniae infection.
Circulation.
1999;
99
1540-1547
-
5
Antiplatelet Trialists Collaboration .
Collaborative
overview of randomized trials of antiplatelet therapy. I: prevention
of death, myocardial infarction and stroke by prolonged antiplatelet
therapy in various categories of patients.
BMJ.
1994;
308
81-106
-
6
Biller J, Feinberg W, Castaldo J. et al .
Guidelines
for carotid endarterectomy: A statement for healthcare professionals
from a Special Writing Group of the Stroke Council, American Heart
Association.
Circulation.
1998;
97
501-509
-
7
Boushey C J, Beresford S A, Omenn G S, Motulsky A G.
A quantitative assessment
of plasma homocysteine as a risk factor for vascular disease: probable
benefits of increasing folic acid intakes.
JAMA.
1995;
274
1049-1057
-
8
Collins R, Peto R, MacMahon S. et al .
Blood pressure, stroke, and coronary heart
disease. Part 2, Short term reductions in blood pressure: overview
of randomized drug trials in their epidemiologic context.
Lancet.
1990;
335
827-838
-
9
Cromwell J, Bartosch W J, Fiore M C, Hasselblad V, Baker T.
Cost-effectiveness
of the clinical practice recommendations in the AHCPR guideline
for smoking cessation. Agency for Health Care Policy Research.
JAMA.
1997;
278
1759-1766
-
10
Dyken M E, Somers V K, Yamada T, Ren Z Y, Zimmerman M B.
Investigating
the relationship between stroke and obstructive sleep apnea.
Stroke.
1996;
27
401-407
-
11
European Atrial Fibrillation
Trial Study Group .
Optimal oral anticoagulattion therapy
in patients with non-rheumatic atrial fibrillation and recent cerebral
ischemia.
N Engl J Med.
1995;
333
5-10
-
12
Executive Committee for the
Asymptomatic Carotid Atherosclerosis Study .
Endarterectomy
for asymptomatic carotid artery stenosis.
JAMA.
1995;
273
1421-1428
-
13
Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J.
Chlamydia pneumoniae
but not cytomegalovirus antibodies are associated with future risk
of stroke and cardiovascular disease.
Stroke.
1999;
30
299-305
-
14
Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M.
Homocysteine in cerebral
macroangiography and microangiopathy.
Lancet.
1999;
353
1586-1587
-
15
Flemming M F, Barry K L, Manwell L B, Johnson K, London R.
Brief
physician advice for problem drinkers.
JAMA.
1997;
277
1039-1045
-
16
Gillman M W, Cupples L A. et al .
Protective
effect of fruits and vegetables on development of stroke in men.
JAMA.
1995;
273
1113-1117
-
17
Gupta S, Leatham E W, Carrington D, Mendall M A, Kaski J C, Camm A J.
Elevated
Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin
in male survivors of myocardial infarction.
Circulation.
1997;
96
404-407
-
18
Gorelick P B, Sacco R L, Smith D B. et al .
Prevention of a first stroke: a review
of guidelines and a multidisciplinary consensus statement from the
National Stroke Association.
JAMA.
1999;
281
1112-1120
-
19
Gorelick P B, Schneck M, Berglund L F, Feinberg W, Goldstone J.
Status
of lipids as a risk factor for stroke.
Neuroepidemiology.
1997;
16
107-115
-
20
Grau A J, Buggle F, Ziegler C. et al .
Association between acute cerebrovascular
ischemia and chronic and recurrent infection.
Stroke.
1997;
28
1724-1729
-
21
Hankey G J, Warlow C P.
Treatment and
secondary prevention of stroke: evidence, costs, and effects on
individuals and populations.
Lancet.
1999;
354
1457-1463
-
22
Jorenby D E, Leischow S J, Nides M A. et al .
A controlled trial of sustained-release
bupropion, a nicotine patch, or both for smoking cessation.
N
Engl J Med.
1999;
340
685-691
-
23
Kawachi I, Colditz G A, Stampfer M J. et al .
Smoking cessation and decreased risk of
stroke in women.
JAMA.
1993;
269
232-236
-
24
Kiely D K, Wolf P A, Cupples L A. et al .
Physical activity and stroke risk: The
Framingham Study.
Am J Epidemiology.
1994;
140
608-620
-
25
Kronmal R A, Hart R G, Manolio T A, Talbert R L, Beauchamp N J, Newman A.
Aspirin use and incident
stroke in the Cardiovascular Health Study.
Stroke.
1998;
29
887-894
-
26
Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A.
Antithrombotic
therapy in atrial fibrillation.
Chest.
1995;
108
352-359
(suppl 4))
-
27
Lee I M, Paffenbarger R S.
Physical
activity and stroke incidence. The Harvard Alumni Health Study.
Stroke.
1998;
29
2049-2054
-
28
Matchar D B, McCrory D C, Bamen H J, Feussner J R.
Medical treatment for
stroke prevention.
Annals Int Med.
1994;
121
41-53
-
29
Mathias K, Jäger H, Sahl H, Hennigs S, Gißler H M.
Die
Endoluminale Therapie der Karotisstenose.
Deutsches Ärzteblatt.
1999;
96
2502-2508
-
30
Messerli F, Grossman E, Goldbourt U.
Are
beta-blockers efficacous as first-line therapy for hypertension
in the elderly? A systematic review.
JAMA.
1998;
279
1903-1907
-
31
Perry I, Refsum H, Morris R, Ebrahim S, Ueland P, Shaper A.
Prospective
study of serum total homocysteine concentration and risk of stroke
in middle-aged British men.
Lancet.
1995;
346
1395-1398
-
32
Prystowsky E N, Benson D W Jr, Fuster V. et al .
Management of patients with atrial fibrillation.
A statement for healthcare professionals. From the Subcommittee
on Electrocardiography and Electrophysiology, American Heart Aosociafion.
Circulation.
1996;
93
1262-1277
-
33
Report of the Quality Standards
Subcommittee of the American Academy of Neurology .
Practice
parameter: Stroke prevention in patients with nonvalvular atrial
fibrillation.
Neurology.
1998;
51
671-673
-
34
Sacco R L, Benjamin E J, Broderick J P. et al .
Risk factors.
Panel Stroke.
1997;
28
1507-1517
-
35
Sacks F M, Pfeffer M A, Moye L A. et al .
The effect of pravastatin on coronary events
after myocardial infarction in patients with average cholesterol
levels. Cholesterol and Recunent Events Trial investigators.
N
Engl J Med.
1996;
335
1001-1009
-
36
Saikku P, Leinonen M, Mattila K J. et al .
Serological evidence of an association
of a novel chlamydia, TWAR, with chronic coronary heart disease
an acute myocardial infarction.
Lancet.
1988;
2
(8618)
983-986
-
37
Scandinavian Simvastatin
Survival Study Group .
Randomized trial of cholesterol
lowering in 4444 patients with coronary heart disease: The Scandinavian
Simvastatin Survival Study.
Lancet.
1994;
344
1383-1389
-
38
SHEP Cooperative Research
Group .
Prevention of stroke by antihypertensive drug
treatment in older persons with isolated systolic hypertension.
JAMA.
1991;
265
3255-3264
-
39
Sievert H, Pfeil W, Bösenberg I, Spies H, Theis R, Beykirch K F.
Primäre Stent-Implantation
in der Arteria carotis interna.
Dtsch med Wschr.
1999;
124
1262-1266
-
40
Steering Committee of the
Physicians Health Study Research Group .
Final report
on the aspirin component of the ongoing Physicians Health Study.
N
Engl J Med.
1989;
321
129-135
-
41
Taylor T N, Davis P H, Tomer J C, Holmes J, Meyer J W, Jacobson M F.
Lifetime
cost of stroke in the United States.
Stroke.
1996;
27
1459-1466
-
42
The Atrial Fibrillation Investigators .
The
efficacy of aspirin in patients with atrial fibrillation: Analysis
of pooled data from 3 randomized trials.
Arch Intern Med.
1997;
157
1237-1240
-
43
The Diabetes Control and
Complications Trial Group .
Effect of intensive diabetes
management on macrovascular events and risk factors in the Diabetes
Control and Complications Trial.
Am J Cardiol.
1995;
75
894-903
-
44
The Joint National Committee
on prevention, detection, evaluation, and treatment of high blood
pressure .
The 6th report of the Joint National Committee
on prevention, detection, evaluation, and treatment of high blood
pressure.
Arch Intern Med.
1997;
157
2413-2446
-
45
The National Cholesterol
Education Program (NCEP) Expert Panel .
Summary of the
second report of the National Cholesterol Education Program (NCEP)
Expert Panel in Adults (Adult Treatment Panel II).
JAMA.
1993;
269
3015-3023
-
46
UK Prospective Diabetes Study
Group .
Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes: UKPDS 33.
Lancet.
1998;
352
837-853
-
47
UK Prospective Diabetes Study
Group .
Tight blood pressure control and risk of macrovascuiar
and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ.
1998;
317
703-713
-
48
Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J.
A prospective
study of plasma homocyst(e)ine and risk of ischemic stroke.
Stroke.
1994;
25
1924-1930
-
49
Wolf P A, Abbott R D, Kannel W B.
Atrial
Fibrillation as an independent risk factor for stroke: The Framingham
Study.
Stroke.
1991;
22
983-988
-
50
Wolf P A, DAgostino R B, Kannel W B, Bonita R Belanger AJ.
Cigarette smoking
as a risk factor for stroke: The Framingliam Study.
JAMA.
1998;
259
1025-1029
Korrespondenz
Dr. med. Florian Buggle
Neurologische Klinik
Im Neuenheimer Feld 400
69120 Heidelberg
Phone: 06221/567504
Fax: 06221/565451
Email: Florian_Buggle@med.uni-heidelberg.de
